Stocks
Fate Therapeutics Financial Statements (FATE) |
||||||||||
| Fate Therapeuticssmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 02.03.2020 | 24.02.2021 | 28.02.2022 | 28.02.2023 | 26.02.2024 | 26.02.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 10.7 | 31.4 | 55.8 | 96.3 | 63.5 | 63.5 | |||
| Operating Income, bln rub | -100.7 | -128.1 | -217.0 | -308.4 | -177.6 | -190.5 | ||||
| EBITDA, bln rub | ? | -96.4 | -125.7 | -215.7 | -308.4 | -159.3 | -177.0 | |||
| Net profit, bln rub | ? | -97.7 | -170.3 | -206.3 | -255.1 | -160.9 | -151.2 | |||
| OCF, bln rub | ? | -83.2 | -39.2 | -162.9 | -248.2 | -132.3 | -132.3 | |||
| CAPEX, bln rub | ? | 7.40 | 4.93 | 50.7 | 35.6 | 6.15 | 6.15 | |||
| FCF, bln rub | ? | -90.6 | -44.2 | -213.6 | -283.8 | -138.4 | -138.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 111.4 | 159.5 | 272.8 | 404.7 | 222.9 | 249.2 | ||||
| Cost of production, bln rub | 87.8 | 125.6 | 5.85 | 13.8 | 18.3 | 18.3 | ||||
| R&D, bln rub | 87.8 | 125.6 | 215.5 | 320.5 | 143.4 | 167.7 | ||||
| Interest expenses, bln rub | 1.75 | 0.000 | 0.000 | 5.84 | 0.000 | 19.4 | ||||
| Assets, bln rub | 302.3 | 622.5 | 921.5 | 705.6 | 506.2 | 506.2 | ||||
| Net Assets, bln rub | ? | 244.8 | 384.4 | 678.8 | 483.9 | 368.4 | 368.4 | |||
| Debt, bln rub | 26.9 | 97.3 | 114.8 | 109.3 | 103.5 | 103.5 | ||||
| Cash, bln rub | 221.4 | 482.9 | 615.9 | 436.2 | 315.2 | 315.2 | ||||
| Net debt, bln rub | -194.5 | -385.6 | -501.1 | -326.9 | -211.6 | -211.6 | ||||
| Ordinary share price, rub | 19.6 | 90.9 | 58.5 | 10.1 | 3.74 | 2.20 | ||||
| Number of ordinary shares, mln | 68.2 | 82.4 | 94.7 | 96.8 | 98.4 | 98.6 | ||||
| Market cap, bln rub | 1 334 | 7 491 | 5 544 | 977 | 368 | 217 | ||||
| EV, bln rub | ? | 1 140 | 7 106 | 5 043 | 650 | 156 | 5 | |||
| Book value, bln rub | 245 | 384 | 679 | 484 | 368 | 368 | ||||
| EPS, rub | ? | -1.43 | -2.07 | -2.18 | -2.63 | -1.64 | -1.53 | |||
| FCF/share, rub | -1.33 | -0.54 | -2.25 | -2.93 | -1.41 | -1.40 | ||||
| BV/share, rub | 3.59 | 4.67 | 7.16 | 5.00 | 3.74 | 3.74 | ||||
| EBITDA margin, % | ? | -902.6% | -399.8% | -386.2% | -320.2% | -250.8% | -278.5% | |||
| Net margin, % | ? | -914.9% | -541.8% | -369.4% | -264.9% | -253.3% | -238.0% | |||
| FCF yield, % | ? | -6.79% | -0.59% | -3.85% | -29.0% | -37.6% | -63.8% | |||
| ROE, % | ? | -39.9% | -44.3% | -30.4% | -52.7% | -43.7% | -41.0% | |||
| ROA, % | ? | -32.3% | -27.4% | -22.4% | -36.1% | -31.8% | -29.9% | |||
| P/E | ? | -13.7 | -44.0 | -26.9 | -3.83 | -2.29 | -1.43 | |||
| P/FCF | -14.7 | -169.6 | -26.0 | -3.44 | -2.66 | -1.57 | ||||
| P/S | ? | 125.0 | 238.3 | 99.3 | 10.1 | 5.79 | 3.41 | |||
| P/BV | ? | 5.45 | 19.5 | 8.17 | 2.02 | 1.00 | 0.59 | |||
| EV/EBITDA | ? | -11.8 | -56.5 | -23.4 | -2.11 | -0.98 | -0.03 | |||
| Debt/EBITDA | 2.02 | 3.07 | 2.32 | 1.06 | 1.33 | 1.20 | ||||
| R&D/CAPEX, % | 1 187% | 2 547% | 425.1% | 901.0% | 2 331% | 2 726% | ||||
| CAPEX/Revenue, % | 69.2% | 15.7% | 90.8% | 36.9% | 9.68% | 9.68% | ||||
| Fate Therapeutics shareholders | ||||||||||
